GlassScriptPhysician profile
Jeremy Jaffe
NPI 1982606182
$24,950.66
in general payments reported to CMS, 2019-2025
63 companies · $2,956 in 2025
The $2,956 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,626 · 2020: $1,632 · 2021: $3,695 · 2022: $5,735 · 2023: $4,657 · 2024: $3,651 · 2025: $2,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,163.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,609.11 | 2019-2025 | Proclaim, Eterna, Octrode |
| Collegium Pharmaceutical, INC. | $2,730.67 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $2,607.87 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,159.58 | 2019-2024 | Relistor |
| Abbvie INC. | $1,073.34 | 2021-2025 | |
| Vertos Medical, INC. | $1,070.56 | 2021-2024 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $794.96 | 2021-2025 | Ztlido |
| Ibsa Pharma INC. | $468.86 | 2022-2025 | Tirosint, Licart, Tirosint |
| Uswm, LLC | $430.27 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $426.62 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $398.78 | 2019-2025 | |
| Valinor Pharma, LLC | $395.22 | 2023-2025 | Movantik |
| Stryker Corporation | $264.71 | 2020-2025 | Mild Device Kit |
| Medtronic, INC. | $250.37 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Vertex Pharmaceuticals Incorporated | $198.36 | 2024-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.